Lifesciences
Built natively on CARA, CARA Publisher publishes submissions in place and validates them continuously, with eCTD v4.0 and v3.2.2, M4Q (R2) and other submission types supported side by side from launch in Q2 2027, using a majority of existing CARA functionality.
LONDON, UK: Generis, a global leader in enterprise content and data management, today announced that CARA Publisher, a new native publishing and submission product, is planned for release in Q2 2027. Regulatory teams will be able to plan, assemble, validate, review and send submissions to health authorities from the same system that already holds their approved content and submission structures and RIM data, without copying documents out into a separate publishing tool.
The announcement comes as the industry prepares for the biggest change to submission publishing in a generation. Japan made eCTD v4.0 mandatory for new applications in April 2026, EMA will make it mandatory for new centralised marketing authorisation applications from Q1 2028, and other regions are following. Every sponsor will need to revisit its publishing stack within the next two years. Most existing tools work by copying documents out of a content system, publishing elsewhere and archiving the result back, which means duplicate storage, duplicate audit trails and late surprises. CARA Publisher removes that step.
“We’re excited to bring this final piece of the regulatory puzzle as we continue our rapid growth journey, including in displacing the traditional market leaders. This is a great step forward for Generis as we double-down on our commitment to making some of the toughest challenges in Life Sciences as effortless and powerful as possible. Our approach to Publishing is “classic CARA” – ultimately flexible and future-proofed by design, seamlessly integrated into our users’ workflow, and enhanced with our governed AI,” said Max Kelleher, CEO at Generis.
CARA Publisher is planned to include:
- Publish in place: Source documents never leave CARA. A submission is built from governed references to approved document versions, so a single record of content, audit trail and validation covers both authoring and publishing. If a source document changes, affected submissions are flagged for review.
- One workspace covering the entire process from planning to approval, acknowledgement, and archival: Submissions are created from regulatory activities in CARA RIM, so product, procedure and country information is entered once. Publishers assemble content against region-aware templates, and agency acknowledgements flow back to update the regulatory record automatically.
- eCTD v4.0 and v3.2.2 in parallel: A single internal model produces either format, so teams can keep working on existing v3.2.2 applications and move to v4.0 when they choose, carrying document identity forward. Non-eCTD formats such as NeeS and vNeeS are also supported, along with import of existing lifecycles from other publishing systems. M4Q (R2) is also supported, including using the CARA AI to convert existing documents into the M4Q (R2) granularity and organisation.
- Continuous validation: Agency criteria are checked as documents change, not once at the end, and issues are linked to the exact item that caused them. A sequence cannot be locked while errors remain, so what is sent to the agency has already passed.
- Regional requirements, vocabularies, validation rules and gateway profiles are delivered as versioned Region Packs, so a change in an agency specification becomes a content / template update rather than a software upgrade.
- Governed AI: CARA AI assists with quality checks, document placement and hyperlinking, accelerating the processes but remaining “AI in the Loop”, with human governance for regulated steps such as review and approval. Every action is recorded in the audit trail.
- Delivery to agencies: Automated gateways will initially be available for the FDA, EMA, Health Canada and PMDA, with assisted dispatch for other markets. Each transmission is stored as an immutable record, including the exact package sent and every receipt, and customers keep control of their own agency credentials.
- Compliance by design: CARA Publisher inherits CARA’s 21 CFR Part 11, EU GMP Annex 11 and GxP posture, with electronic signatures at QC approval and dispatch, and an agency-style viewer that can also give partners and CROs read-only access.
Because CARA Publisher is delivered on the CARA platform, it is configurable in the same way as the rest of CARA, available through the CARA REST API, and can be deployed as SaaS in CARA Cloud or alongside existing customer-hosted environments. It will be available to new and existing CARA Life Sciences customers in 2027, with further releases adding capabilities for medical devices, larger-scale bulk operations and additional markets.
For more information on CARA Publisher, contact sales@generiscorp.com.
About Generis
Generis is a global leader in enterprise content and data management, offering the CARA Platform and the CARA Life Sciences Platform, trusted by leading organisations in life sciences, finance, oil and gas, and other highly regulated industries. CARA provides a seamless, highly configurable user experience with advanced AI, security and now integrated submission publishing capabilities, enabling organisations to manage their data and workflows efficiently and compliantly.
